A Phase 3 interventional study of Prednisone and Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate) in Systemic Lupus Erythematosus, sponsored by Genentech, Inc.. Terminated. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2020-09-17.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche — 2 open to participants now, 4 under way, 1 of them phase 3. Lupus Erythematosus, Systemic · Hoffmann-La Roche.
Among the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, this one is the 10th largest by enrollment, is one of 2 that started in 2007, is one of 4 in phase 3, and was the 3rd registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →2 of the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche are open now, in 10 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in Australia, Brazil, China and 3 more countries
Ages 18–75
Hoffmann-La Roche · Sites in Argentina, Brazil, Colombia and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 5
First in 2005; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 65 across the 14 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
1 of the studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05835986Hoffmann-La RocheA First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase III, randomized, double blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of ocrelizumab compared to placebo when combined with a single stable background immunosuppressive medication and a corticosteroid regimen in patients with moderately to severely active systemic lupus erythematosus, who do not have moderate to severe glomerulonephritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ocrelizumab was administered i.v. at a dose on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks
Drug: Prednisone · Drug: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate) · Drug: Methylprednisolone · Drug: Ocrelizumab
Ocrelizumab was administered at a dose 400 mg i.v. on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks
Drug: Prednisone · Drug: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate) · Drug: Methylprednisolone · Drug: Ocrelizumab
Placebo infusions were administered on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks
Drug: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate) · Drug: Placebo
Oral repeating dose
Oral repeating dose
Intravenous repeating dose
Intravenous repeating dose
Intravenous repeating dose
Number of Participants With Major Clinical Response (MCR)
Time frame: Week 48
Number of Participants With Partial Clinical Response (PCR)
Time frame: Week 48
Number of Non-responders (NR)
Time frame: Week 48
Number of Participants Who Achieved a BILAG Score of C or Better at Week 24.
Time frame: Week 24
Time Adjusted Mean SLEDAI-2K Score
Time frame: Week 48
Annualized Flare Rate
Time frame: Week 48 to Week 96
Time to First Moderate to Severe Flare
Time frame: Week 48 to Week 96
Number of Participants Who Achieved A Major Or Partial Clinical Response At Week 48 (PCR Plus MCR Proportion), Who Did Not Experience A Flare Before Week 96
Time frame: Week 48 to Week 96
Number of Participants Who Achieved A MCR At Week 48, Who Did Not Experience A Flare Before Week 72
Time frame: Week 48 to Week 72
Number of Participants Achieved A MCR At Week 48, Who Did Not Experience A Flare Before Week 96
Time frame: Week 48 to Week 96
Change in SF-36 Subscale And Summary Scores From Baseline At Week 48
Time frame: Baseline, Week 48
Change In FACIT-Fatigue Assessment From Baseline To Week 48
Time frame: Baseline, Week 48
Change From Baseline In Pain Quality And Impact Of Pain On Daily Function Measured By The Brief Pain Inventory Short Form At Week 48
Time frame: Baseline, Week 48
The EQ-5D Single Index Utility Score At Week 48
Time frame: Baseline, Week 48
Number of Participants With Adverse Events
Time frame: Up to 2.5 years
A maximum screening window of 14 days was allowed.
| Milestone | Ocrelizumab 1000 mg | Ocrelizumab 400 mg | Placebo |
|---|---|---|---|
| Started | 12 | 11 | 10 |
| Completed | 5 | 5 | 1 |
| Not completed | 7 | 6 | 9 |
| Withdrew: Fail to return | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 | 0 |
| Withdrew: Death | 0 | 2 | 0 |
| Withdrew: Did not cooperate | 1 | 0 | 1 |
| Withdrew: Administrative | 4 | 0 | 8 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over Baseline up to 42 months.. Non-serious events are listed at a 0.05% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/10 (0%) | 5/10 (50%) |
| Ocrelizumab 400 mg | — | 6/11 (54.5%) | 10/11 (90.9%) |
| Ocrelizumab 1000 mg | — | 3/12 (25%) | 8/12 (66.7%) |
| Event | Placebo | Ocrelizumab 400 mg | Ocrelizumab 1000 mg |
|---|---|---|---|
| CYTOMEGALOVIRUSInfections and infestations | 0/10 | 1/11 | 0/12 |
| CHORIORETINITISInfections and infestations | 0/10 | 1/11 | 0/12 |
| PNEUMONIAInfections and infestations | 0/10 | 1/11 | 0/12 |
| SEPTIC SHOCKInfections and infestations | 0/10 | 1/11 | 0/12 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/10 | 1/11 | 0/12 |
| URINARY TRACT INFECTIONInfections and infestations | 0/10 | 1/11 | 0/12 |
| NEPHROTIC SYNDROMERenal and urinary disorders | 0/10 | 1/11 | 0/12 |
| RENAL FAILURERenal and urinary disorders | 0/10 | 1/11 | 0/12 |
| ANAEMIABlood and lymphatic system disorders | 0/10 | 1/11 | 0/12 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 0/10 | 1/11 | 0/12 |
| Event | Placebo | Ocrelizumab 400 mg | Ocrelizumab 1000 mg |
|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/10 | 3/11 | 2/12 |
| URINARY TRACT INFECTIONInfections and infestations | 1/10 | 3/11 | 1/12 |
| DIARRHOEAGastrointestinal disorders | 0/10 | 3/11 | 1/12 |
| BRONCHITISInfections and infestations | 0/10 | 0/11 | 3/12 |
| SINUSITISInfections and infestations | 0/10 | 2/11 | 1/12 |
| NAUSEAGastrointestinal disorders | 1/10 | 2/11 | 1/12 |
| VOMITINGGastrointestinal disorders | 1/10 | 2/11 | 0/12 |
| HEADACHENervous system disorders | 1/10 | 2/11 | 1/12 |
| INSOMNIAPsychiatric disorders | 0/10 | 2/11 | 2/12 |
| INFUSION RELATED REACTIONGeneral disorders | 0/10 | 2/11 | 1/12 |
| Age, Continuous(Years) | Placebo | Ocrelizumab 400 mg | Ocrelizumab 1000 mg | Total |
|---|---|---|---|---|
| Mean | 41.0 ± 13.82 | 40.2 ± 8.80 | 36.3 ± 11.31 | 39.0 ± 11.24 |
| Sex: Female, Male(Participants) | Placebo | Ocrelizumab 400 mg | Ocrelizumab 1000 mg | Total |
|---|---|---|---|---|
| Female | 9 | 11 | 10 | 30 |
| Male | 1 | 0 | 2 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Ocrelizumab 400 mg | Ocrelizumab 1000 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 2 | 4 | 12 |
| Not Hispanic or Latino | 4 | 9 | 8 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Ocrelizumab 400 mg | Ocrelizumab 1000 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 1 | 3 | 8 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 | 4 |
| White | 5 | 8 | 7 | 20 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Dec 2007 to primary completion in Jul 2011, 42 months.
Results were first posted in Sep 2020, 9 years 2 months after primary completion. A results delay was requested in Jan 2013.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab
Lupus Erythematosus, Systemic →